Citation only
via Europe PMC
Comparison of Aflibercept and Brolucizumab in Treatment-Naïve Neovascular Age-related Macular Degeneration with Thick Pigment Epithelial Detachments.
Lee IG, Kim HD, Cho IH, Lee CH.
Korean journal of ophthalmology : KJO · 2026
Abstract
<h4>Purpose</h4>To compare short-term anatomical and functional outcomes of intravitreal brolucizumab versus aflibercept in treatment-naïve neovascular age-related macular degeneration (nAMD) with thick pigment epithelial detachments (PEDs).<h4>Methods</h4>This retrospective comparative study included treatment-naïve nAMD eyes with thick PEDs (maximum PED height ≥250 μm) treated with intravitreal aflibercept or brolucizumab between January 2022 and June 2025, with a minimum 6-month follow-up. The primary outcome was anatomical response at Month 6, defined as ≥50% reduction in maximum PED height. Secondary outcomes included changes in best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), qualitative OCT features, injection burden, and safety. Longitudinal changes were analyzed using linear mixed-effects models.<h4>Results</h4>Forty-one eyes (aflibercept, n=21; brolucizumab, n=20) were included. Baseline BCVA, CFT, and PED height did not differ significantly between the groups, although SFCT was thicker in the brolucizumab group (P=0.034). Over 6 months, the mean number of injections was significantly lower with brolucizumab (3.05 ± 0.40 vs. 3.86 ± 0.65, P<0.001). Brolucizumab achieved greater reduction in PED height at Month 3 (P=0.014) and Month 6 (P=0.044). In mixed-effects analysis, all anatomical parameters and BCVA improved over time (Ptime<0.001). SFCT demonstrated significant group and interaction effects (Pgroup=0.031; Pint=0.006), whereas PED height and CFT did not. Residual subretinal hyperreflective material was less frequent at Month 3 with brolucizumab (0.0% vs. 23.8%, P=0.048). No intraocular inflammation occurred.<h4>Conclusions</h4>In treatment-naïve nAMD eyes with thick PEDs, brolucizumab was associated with greater short-term anatomical improvement and a lower injection burden compared with aflibercept, whereas no statistically significant between-group difference was observed in BCVA change. Further studies with larger cohorts and longer follow-up are warranted to confirm these findings.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3341/kjo.2026.0032
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
IG, L., HD, K., IH, C., & CH., L. (2026). Comparison of Aflibercept and Brolucizumab in Treatment-Naïve Neovascular Age-related Macular Degeneration with Thick Pigment Epithelial Detachments. <em>Korean journal of ophthalmology : KJO</em>. https://doi.org/10.3341/kjo.2026.0032
Vancouver
IG L, HD K, IH C, CH. L. Comparison of Aflibercept and Brolucizumab in Treatment-Naïve Neovascular Age-related Macular Degeneration with Thick Pigment Epithelial Detachments. Korean journal of ophthalmology : KJO. 2026. doi:10.3341/kjo.2026.0032.
BibTeX
@article{lee2026Compar,
title = {Comparison of Aflibercept and Brolucizumab in Treatment-Naïve Neovascular Age-related Macular Degeneration with Thick Pigment Epithelial Detachments.},
author = {Lee IG and Kim HD and Cho IH and Lee CH.},
journal = {Korean journal of ophthalmology : KJO},
year = {2026},
doi = {10.3341/kjo.2026.0032},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Vision (Basel, Switzerland) 2026
Open access · OA
Outcomes of Intravitreal Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Kazakhstan.
BMC ophthalmology 2026
Citation only
Real-world outcomes of faricimab in treatment-naïve patients with neovascular age-related macular degeneration.
International journal of ophthalmology 2026
Citation only
Efficacy and safety of intravitreal conbercept treat-and-extend regimens in neovascular age-related macular degeneration.
Retina 2006
Citation only
INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Ophthalmology 2013
Citation only
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Ophthalmology 2019
Open access · CC-BY